Abstract
Neoadjuvant chemoradiotherapy (CRT) and surgery is a treatment option for patients with locally advanced stage non-small cell lung cancer (NSCLC) with limited mediastinal lymph node metastases. Pathological complete response (pCR) correlates with improved survival but is achieved in only approximately 30% of patients after CRT. Neo-adjuvant ipilimumab plus nivolumab (IPI-NIVO) can modulate the tumor microenvironment and may increase pathological responses. In a phase II study (INCREASE, EudraCT-Nr: 2019–003454-83), we studied the addition of IPI-NIVO to CRT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
